Ac-SDKP vs EGF
Head-to-head comparison of Ac-SDKP (N-Acetyl-Seryl-Aspartyl-Lysyl-Proline) and EGF (Human Epidermal Growth Factor) — benefits, dosing, side effects, research data, and where to buy.
| Property | Ac-SDKP | EGF |
|---|---|---|
| Category | Recovery & Healing | Recovery & Healing |
| Full Name | N-Acetyl-Seryl-Aspartyl-Lysyl-Proline | Human Epidermal Growth Factor |
| Molecular Weight | 432.4 Da | 6.0 kDa |
| Half-Life | minutes | minutes |
| Amino Acids | 4 | 53 |
| Typical Dose | 10–100 µg/kg/day in pre-clinical studies | 0.04–0.1 mg/cm²/day |
| Route | Subcutaneous | Topical |
| Purity | ≥98% | ≥98% |
| Studies Count | 180 | 650 |
| Research Status | Pre-clinical | Clinical |
Ac-SDKP Benefits
- ✓anti-inflammatory tissue remodeling
- ✓fibroblast modulation
- ✓microvascular protection
- ✓faster regenerative signaling
EGF Benefits
- ✓re-epithelialization
- ✓fibroblast activation
- ✓angiogenesis support
- ✓faster ulcer closure
Ac-SDKP Dosing
Research-only systemic microdoses|short daily dosing in animal models|route varies by study
EGF Dosing
Topical daily|0.04–0.1 mg/cm²|short courses until granulation/closure
Ac-SDKP Side Effects
- ⚠GI upset
- ⚠hypotension at high exposure
- ⚠unknown long-term safety
EGF Side Effects
- ⚠local irritation
- ⚠erythema
- ⚠theoretical hyperproliferation
- ⚠pain at site
Research Overview
Ac-SDKP
Ac-SDKP has literature in tissue remodeling, angiogenesis, and organ repair models. Its strongest evidence is pre-clinical, where it modulates inflammation and fibrosis during healing.
EGF
Human and animal studies show EGF can accelerate epithelial migration and wound closure, especially in burns, ulcers, and mucosal injury. Its best evidence is for topical or local delivery because systemic exposure is brief and the effect is highly localized.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.